Literature DB >> 11918684

Regulation of inflammatory responses by natural anticoagulants.

K Okajima1.   

Abstract

Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are critically involved in activation of the coagulation system in sepsis, leading to disseminated intravascular coagulation (DIC). Natural anticoagulants such as antithrombin (AT) and activated protein C (APC) regulate the coagulation system by inhibiting thrombin generation. In addition to these anticoagulant effects, both AT and APC have been shown to attenuate inflammatory responses induced by various noxious stimuli in rats such as lipopolysaccharide (LPS) challenge. AT promotes the endothelial release of prostacyclin, a potent anti-inflammatory prostaglandin that inhibits the monocytic production of TNF-alpha, by interacting with cell-surface heparin-like substances. APC directly inhibits the production of TNF-alpha by inhibiting the activation of both nudear factor kappaB (NFkappaB) and activator protein-1 in monocytes stimulated with LPS. Thrombomodulin, an endothelial membranous integral protein that binds thrombin, exerts anti-inflammatory effects by generating APC. Furthermore, tissue factor pathway inhibitor, a natural anticoagulant for the extrinsic pathway of the coagulation system, also attenuates LPS-induced inflammatory responses in rats by inhibiting TNF-alpha production by monocytes. These findings strongly suggest that natural anticoagulants could regulate inflammatory responses as well as the coagulation system in rats by inhibiting the monocytic production of TNF-alpha. Such anti-inflammatory properties of natural anticoagulants are potentially important for their replacement in patients with sepsis who frequently develop DIC and organ failure as inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11918684     DOI: 10.1034/j.1600-065x.2001.1840123.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  26 in total

1.  Fever six weeks after trauma.

Authors:  C J Boos; P Allen; R More; T Lancaster; M Dawes
Journal:  J R Soc Med       Date:  2003-04       Impact factor: 5.344

Review 2.  Blood coagulation disorders in septic patients.

Authors:  Paul Knoebl
Journal:  Wien Med Wochenschr       Date:  2010-03

Review 3.  Activated protein C action in inflammation.

Authors:  Pranita P Sarangi; Hyun-wook Lee; Minsoo Kim
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

Review 4.  Antithrombin in the treatment of burn trauma.

Authors:  Areta Kowal-Vern; Bruce A Orkin
Journal:  World J Crit Care Med       Date:  2016-02-04

Review 5.  Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion.

Authors:  Albe C Swanepoel; Vance G Nielsen; Etheresia Pretorius
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

6.  Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministration of tranexamic acid.

Authors:  Hidesaku Asakura; Yoko Sano; Tomotaka Yoshida; Mika Omote; Yasuo Ontachi; Tomoe Mizutani; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Intensive Care Med       Date:  2004-06-15       Impact factor: 17.440

7.  RNA-binding protein HuR interacts with thrombomodulin 5'untranslated region and represses internal ribosome entry site-mediated translation under IL-1 beta treatment.

Authors:  Chiu-Hung Yeh; Liang-Yi Hung; Chin Hsu; Shu-Yun Le; Pin-Tse Lee; Wan-Lin Liao; Yi-Tseng Lin; Wen-Chang Chang; Joseph T Tseng
Journal:  Mol Biol Cell       Date:  2008-06-25       Impact factor: 4.138

8.  Significance of decreased plasma D-dimer levels following lipopolysaccharide-induced disseminated intravascular coagulation in rats.

Authors:  Hidesaku Asakura; Yoko Sano; Mika Omote; Tomotaka Yoshida; Yasuo Ontachi; Tomoe Mizutani; Minori Kaneda; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

Review 9.  Protective mechanisms of activated protein C in severe inflammatory disorders.

Authors:  Arne P Neyrinck; Kathleen D Liu; James P Howard; Michael A Matthay
Journal:  Br J Pharmacol       Date:  2009-05-14       Impact factor: 8.739

10.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.